Seek Returns logo

ABBV vs. JPM: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at ABBV and JPM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolABBVJPM
Company NameAbbVie Inc.JPMorgan Chase & Co.
CountryUnited StatesUnited States
GICS SectorHealth CareFinancials
GICS IndustryBiotechnologyBanks
Market Capitalization413.22 billion USD852.51 billion USD
ExchangeNYSENYSE
Listing DateJanuary 2, 2013March 17, 1980
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of ABBV and JPM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. JPM: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolABBVJPM
5-Day Price Return4.82%-1.79%
13-Week Price Return23.58%4.74%
26-Week Price Return11.64%26.39%
52-Week Price Return18.84%49.56%
Month-to-Date Return1.02%-1.71%
Year-to-Date Return31.63%29.34%
10-Day Avg. Volume6.76M7.89M
3-Month Avg. Volume5.66M8.32M
3-Month Volatility23.82%17.07%
Beta0.361.10

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry

Max
97.92%
Q3
11.99%
Median
-19.30%
Q1
-51.29%
Min
-132.03%

In the upper quartile for the Biotechnology industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

JPM

16.16%

Banks Industry

Max
25.40%
Q3
15.55%
Median
12.00%
Q1
8.98%
Min
-0.10%

In the upper quartile for the Banks industry, JPM’s Return on Equity of 16.16% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

ABBV vs. JPM: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Banks industry benchmarks.

Net Profit Margin (TTM)

ABBV

6.45%

Biotechnology Industry

Max
73.34%
Q3
18.98%
Median
-12.96%
Q1
-105.72%
Min
-259.82%

ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

JPM

33.26%

Banks Industry

Max
54.20%
Q3
35.73%
Median
28.97%
Q1
22.56%
Min
6.98%

JPM’s Net Profit Margin of 33.26% is aligned with the median group of its peers in the Banks industry. This indicates its ability to convert revenue into profit is typical for the sector.

ABBV vs. JPM: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Banks industry benchmarks.

Operating Profit Margin (TTM)

ABBV

18.80%

Biotechnology Industry

Max
78.85%
Q3
21.90%
Median
-13.30%
Q1
-109.94%
Min
-278.10%

ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

JPM

41.23%

Banks Industry

Max
63.35%
Q3
44.73%
Median
37.24%
Q1
28.25%
Min
12.28%

JPM’s Operating Profit Margin of 41.23% is around the midpoint for the Banks industry, indicating that its efficiency in managing core business operations is typical for the sector.

ABBV vs. JPM: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Banks industry benchmarks.

Profitability at a Glance

SymbolABBVJPM
Return on Equity (TTM)95.59%16.16%
Return on Assets (TTM)2.73%1.32%
Net Profit Margin (TTM)6.45%33.26%
Operating Profit Margin (TTM)18.80%41.23%
Gross Profit Margin (TTM)70.93%--

Financial Strength

Current Ratio (MRQ)

ABBV

0.74

Biotechnology Industry

Max
16.97
Q3
8.39
Median
4.11
Q1
2.64
Min
0.74

ABBV’s Current Ratio of 0.74 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

JPM

--

Banks Industry

Max
--
Q3
--
Median
--
Q1
--
Min
--

For the Banks industry, the Current Ratio is often not the most suitable measure of short-term liquidity.

ABBV vs. JPM: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Banks industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry

Max
1.92
Q3
0.79
Median
0.12
Q1
0.00
Min
0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

JPM

3.03

Banks Industry

Max
5.78
Q3
2.66
Median
1.05
Q1
0.40
Min
0.00

The Debt-to-Equity Ratio is often not the primary focus for assessing leverage in the Banks industry.

ABBV vs. JPM: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Banks industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

2.70

Biotechnology Industry

Max
72.37
Q3
1.03
Median
-9.59
Q1
-65.05
Min
-163.11

ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

JPM

--

Banks Industry

Max
--
Q3
--
Median
--
Q1
--
Min
--

The Interest Coverage Ratio is often not a primary indicator of debt servicing capacity in the Banks industry.

ABBV vs. JPM: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Banks industry benchmarks.

Financial Strength at a Glance

SymbolABBVJPM
Current Ratio (MRQ)0.74--
Quick Ratio (MRQ)0.48--
Debt-to-Equity Ratio (MRQ)49.223.03
Interest Coverage Ratio (TTM)2.70--

Growth

Revenue Growth

ABBV vs. JPM: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ABBV vs. JPM: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ABBV

2.71%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ABBV’s Dividend Yield of 2.71% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

JPM

1.83%

Banks Industry

Max
11.03%
Q3
6.00%
Median
3.87%
Q1
2.41%
Min
0.00%

JPM’s Dividend Yield of 1.83% is in the lower quartile for the Banks industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.

ABBV vs. JPM: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Banks industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

226.84%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

JPM

27.49%

Banks Industry

Max
134.24%
Q3
79.39%
Median
55.09%
Q1
36.09%
Min
0.00%

JPM’s Dividend Payout Ratio of 27.49% is in the lower quartile for the Banks industry. This suggests a conservative dividend policy, with a strategic focus on reinvesting profits for future growth.

ABBV vs. JPM: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Banks industry benchmarks.

Dividend at a Glance

SymbolABBVJPM
Dividend Yield (TTM)2.71%1.83%
Dividend Payout Ratio (TTM)226.84%27.49%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

111.05

Biotechnology Industry

Max
40.44
Q3
39.37
Median
22.12
Q1
15.76
Min
3.48

At 111.05, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

JPM

15.06

Banks Industry

Max
22.69
Q3
13.75
Median
10.32
Q1
7.73
Min
2.59

A P/E Ratio of 15.06 places JPM in the upper quartile for the Banks industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

ABBV vs. JPM: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Banks industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

7.16

Biotechnology Industry

Max
92.67
Q3
41.36
Median
8.45
Q1
4.46
Min
0.97

ABBV’s P/S Ratio of 7.16 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

JPM

2.90

Banks Industry

Max
4.90
Q3
2.98
Median
2.24
Q1
1.59
Min
0.45

The P/S Ratio is often not a primary valuation tool in the Banks industry.

ABBV vs. JPM: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Banks industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry

Max
22.72
Q3
10.68
Median
4.55
Q1
2.44
Min
0.59

At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

JPM

2.26

Banks Industry

Max
2.09
Q3
1.40
Median
1.11
Q1
0.86
Min
0.29

At 2.26, JPM’s P/B Ratio is at an extreme premium to the Banks industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

ABBV vs. JPM: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Banks industry benchmarks.

Valuation at a Glance

SymbolABBVJPM
Price-to-Earnings Ratio (TTM)111.0515.06
Price-to-Sales Ratio (TTM)7.162.90
Price-to-Book Ratio (MRQ)261.012.26
Price-to-Free Cash Flow Ratio (TTM)22.914.80